用药方案 | 顺位 | 总人数(N = 3943) | 早发性患者(N = 356) | 迟发性患者(N = 3137) | P* |
单一用药 |
| 751 (21.5) | 118 (33.1) | 633 (20.2) | <0.001 |
Insulin | 1 | 391 (52.1) | 82 (69.5) | 309 (48.8) | <0.001 |
MET | 2 | 208 (27.7) | 26 (22.0) | 182 (28.8) | 0.134 |
AGI | 3 | 49 (6.5) | 3 (2.5) | 46 (7.3) | 0.056 |
DDP-4i | 4 | 43 (5.7) | 4 (3.4) | 39 (6.2) | 0.234 |
SUs | 5 | 26 (3.5) | 0 (0) | 26 (4.1) | 0.025 |
二联用药 |
| 926 (26.5) | 79 (22.2) | 847 (27.0) | 0.051 |
MET + Insulin | 1 | 187 (20.2) | 35 (44.3) | 152 (17.9) | <0.001 |
AGI + Insulin | 2 | 130 (14.0) | 11 (13.9) | 119 (14.0) | 0.975 |
MET + SUs | 3 | 102 (11.0) | 3 (3.8) | 99 (11.7) | 0.032 |
Glinides + Insulin | 4 | 89 (9.6) | 1 (1.3) | 88 (10.4) | 0.009 |
MET + AGI | 5 | 70 (7.6) | 3 (3.8) | 67 (7.9) | 0.186 |
三联用药 |
| 915 (26.2) | 76 (21.3) | 839 (26.7) | 0.028 |
MET + DDP-4i + Insulin | 1 | 190 (20.8) | 29 (38.2) | 161 (19.2) | <0.001 |
MET + AGI + Insulin | 2 | 134 (14.6) | 17 (22.4) | 117 (13.9) | 0.047 |
MET + SUs + AGI | 3 | 66 (7.2) | 4 (5.3) | 62 (7.4) | 0.493 |
MET + SGLT-2i + Insulin | 4 | 62 (6.8) | 6 (7.9) | 56 (6.7) | 0.685 |
MET + Glinide + Insulin | 5 | 55 (6.0) | 2 (2.6) | 53 (6.3) | 0.196 |
四联及以上联合用药& |
| 901 (25.8) | 83 (23.3) | 818 (26.1) | 0.259 |